Immunogenic Targets for Therapeutic Vaccination for Liver Cancer

• Conditions: liver cancer; primary liver cancer; 10019815

• Registration Number: NL-OMON42346
• Lead Sponsor: Maag Darm Leverziekten, Clinical Research Bureau

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 360

Inclusion Criteria

Adult HCC-patients treated with RFA, TACE, or surgical resection in Erasmus MC, who are planned to be followed up in Erasmus MC for at least 3 months after the intervention.

Exclusion Criteria

Patients who refuse to participate in the study (refusing blood/tissue donation).
Patients with a severe immunocompromised medical condition, or patients taking immunosuppressing medication.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Determination of tumour antigens and viral antigens that are target of<br /><br>naturally occurring T cell and antibody responses upon tumour destruction or<br /><br>debulking by currently applied therapeutic interventions. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None</p><br>